Drug reference

Meloxicam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1231, 1232

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Exacerbation of osteoarthritis (short-term) ▶BY MOUTH ▶Child 16–17 years: 7.5 mg once daily, then increased if necessary up to 15 mg once daily ▶Adult: 7.5 mg once daily, then increased if necessary up to 15 mg once daily Pain and inflammation in rheumatic disease | Ankylosing spondylitis ▶BY MOUTH ▶Child 16–17 years: 15 mg once daily, then reduced to 7.5 mg once daily if required ▶Adult: 15 mg once daily, then reduced to 7.5 mg once daily if required ▶Elderly: 7.5 mg once daily Relief of pain and inflammation in juvenile idiopathic arthritis and other musculoskeletal disorders in children intolerant to other NSAIDs ▶BY MOUTH ▶Child 12–17 years (body-weight up to 50 kg): 7.5 mg once daily ▶Child 12–17 years (body-weight 50 kg and above): 15 mg once daily l UNLICENSED USE Not licensed for use in children under 16 years.

PDF page 1231

Contra Indications

Active gastro-intestinal bleeding. active gastro-intestinal ulceration. following coronary artery bypass graft surgery. history of gastro-intestinal bleeding related to previous NSAID therapy. history of gastro-intestinal perforation related to previous NSAID therapy. history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes). history of recurrent gastro-intestinal ulceration (two or more distinct episodes). severe heart failure

PDF page 1231

Cautions

Allergic disorders. cardiac impairment (NSAIDs may impair renal function). cerebrovascular disease. coagulation defects. connective-tissue disorders. dehydration (risk of renal impairment). elderly (risk of serious side-effects and fatalities). heart failure. history of gastro-intestinal disorders (e.g. ulcerative colitis, Crohn’s disease). ischaemic heart disease. peripheral arterial disease. risk factors for cardiovascular events. uncontrolled hypertension

PDF page 1232

Allergy And Cross Sensitivity

Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

PDF page 1232

Safety

Interactions

→Appendix 1: NSAIDs

PDF page 1232

Side Effects

▶Common or very common Constipation. diarrhoea. gastrointestinal discomfort. gastrointestinal disorders. headache. nausea. vomiting ▶Uncommon Anaemia. angioedema. burping. dizziness. Musculoskeletal system drowsiness. electrolyte imbalance. ﬂuid retention. ﬂushing. haemorrhage. hepatic disorders. hypersensitivity. oedema. skin reactions. stomatitis. vertigo ▶Rare or very rare Acute kidney injury. asthma. conjunctivitis. leucopenia. mood altered. nightmare. palpitations. severe cutaneous adverse reactions (SCARs). thrombocytopenia. tinnitus. vision disorders ▶Frequency not known Agranulocytosis. confusion. fertility decreased female. heart failure. increased risk of arterial thromboembolism. nephritis tubulointerstitial. nephrotic syndrome. photosensitivity reaction. renal necrosis SIDE-EFFECTS, FURTHER INFORMATION For information about cardiovascular and gastrointestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non- steroidal anti-inﬂammatory drugs. p. 1193

PDF page 1232

Conception And Contraception

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PDF page 1232

Pregnancy

Avoid unless the potential beneﬁt outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

PDF page 1232

Breast Feeding

Use with caution during breast-feeding. Present in milk in animal studies—manufacturer advises avoid.

PDF page 1232

Hepatic Impairment

Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.

PDF page 1232

Renal Impairment

Avoid if possible or use with caution. ▶In adults Avoid if eGFR less than 25 mL/minute/1.73 m2. ▶In children Avoid if estimated glomerular ﬁltration rate less than 25 mL/minute/1.73 m2. Dose adjustments The lowest effective dose should be used for the shortest possible duration. Monitoring In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

PDF page 1232

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Orodispersible tablet ▶Meloxicam (Non-proprietary) Meloxicam 7.5 mg Meloxicam 7.5mg orodispersible tablets sugar free sugar-free | 30 tablet P £25.50 DT = £25.50 Meloxicam 15 mg Meloxicam 15mg orodispersible tablets sugar free sugar-free | 30 tablet P £25.50 DT = £25.50 Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Meloxicam (Non-proprietary) Meloxicam 7.5 mg Meloxicam 7.5mg tablets | 30 tablet P £3.60 DT = £2.92 Meloxicam 15 mg Meloxicam 15mg tablets | 30 tablet P £7.35 DT = £5.26

PDF page 1232

Dose text by age group

Elderly

7.5 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1231

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Meloxicam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1231, 1232

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1231

Contra Indications

PDF page 1231

Cautions

PDF page 1232

Allergy And Cross Sensitivity

PDF page 1232

Safety

Interactions

→Appendix 1: NSAIDs

PDF page 1232

Side Effects

PDF page 1232

Conception And Contraception

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PDF page 1232

Pregnancy

PDF page 1232

Breast Feeding

Use with caution during breast-feeding. Present in milk in animal studies—manufacturer advises avoid.

PDF page 1232

Hepatic Impairment

Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.

PDF page 1232

Renal Impairment

PDF page 1232

Dose and formulations

Medicinal Forms

PDF page 1232

Dose text by age group

Elderly

7.5 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1231

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.